Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pradaxa Available in the UK for DVT, PE

July 15, 2014 11:23 am | News | Comments

Boehringer Ingelheim has announced that Pradaxa will be commercially available in the UK for the treatment of DVT and PE - dangerous conditions with over 25,000 deaths estimated to occur in hospitalized patients each year in the UK - and the prevention of recurrent DVT and PE in adults, from Tuesday. Read more...


Centralized Data Management Improves Collaboration

July 15, 2014 11:16 am | by Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS | Articles | Comments

Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...


U.S. Drug Companies Look Overseas for Tax Relief

July 15, 2014 11:02 am | by Tom Murphy, AP Business Writer | News | Comments

A growing number of U.S. companies are looking to trim their tax bills by combining operations with foreign businesses in a trend that may eventually cost the federal government billions of dollars in revenue. For example, generic drugmaker Mylan Inc. said Monday it will become part of a new company organized in the Netherlands. Read more...


Worldwide Alzheimer's, Dementia Epidemic Grows

July 15, 2014 10:54 am | News | Comments

While the global epidemic of Alzheimer's disease continues to grow, new data on lower incidence in the "youngest old" from developed countries in Europe and the United States suggest the possibility of reducing risk and/or preventing the disease, according to the results of research studies announced at the Alzheimer's Association International Conference 2014. Read more...


Hepatitis Drug Boosts J&J Profits in Q2

July 15, 2014 9:23 am | by Linda A. Johnson, AP Business Writer | News | Comments

Strong sales of several new drugs, particularly its hot new hepatitis medicine, lifted Johnson & Johnson's second-quarter profit by 13%, topping analysts' expectations. Read more...                    


Cannabis Compound Could Slow Tumor Growth, Research Shows

July 14, 2014 2:26 pm | News | Comments

Scientists have shown how the main psychoactive ingredient in cannabis could reduce tumor growth in cancer patients. Read more...                                   


Combo Therapy More Effective in Removing Beta-Amyloid from Mice Brains

July 14, 2014 2:19 pm | News | Comments

Eli Lilly and Co. announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE. Read more...      


Janssen Pharmaceuticals Seeks Expanded Label for Invega Sustenna

July 14, 2014 2:14 pm | News | Comments

Janssen Pharmaceuticals announced the submission of a supplemental New Drug Application to the FDA seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic Invega Sustenna. Read more...


Antibody Halts Cancer-Related Wasting Condition

July 14, 2014 2:05 pm | News | Comments

New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle that occurs in about half of all cancer patients, raising their risk of death. Read more...             


Senators Seek Details on Gilead's Solvaldi Pricing

July 14, 2014 1:53 pm | News | Comments

Senate Finance Committee Chairman Ron Wyden, D-Ore., and senior Finance Committee member Chuck Grassley, R-Iowa, are requestinh detailed pricing information on the costly new Hepatitis C virus (HCV) drug Solvaldi. Read more...        


New Technology Delivers Cargo, Doesn’t Disrupt Cell

July 14, 2014 10:59 am | News | Comments

Portage Biotech announced that Portage Pharmaceuticals has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes that delivers an active pharmacological agent or cargo into a cell without disrupting the cell membrane. Read more...


Mylan to Buy Abbott Generic-Drugs Business for $5.3B

July 14, 2014 10:50 am | News | Comments

The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion in a deal that will diversify and expand its business outside the U.S. when the combined company is organized in the Netherlands. Read more...


Oral Drug Improves Vision in Patients with Inherited Blindness

July 14, 2014 10:43 am | News | Comments

An international research project, led by the Research Institute of the McGill University Health Centre in Montreal, reported that a new oral medication is showing significant progress in restoring vision to patients with Leber congenital amaurosis (LCA). Read more...


Melanoma Drug Combo Meets Primary Endpoint

July 14, 2014 10:34 am | News | Comments

Roche announced that the Phase 3 coBRIM study met its primary endpoint when it demonstrated that cobimetinib, used in combination with Zelboraf, helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer without their disease worsening compared to Zelboraf alone. Read more...


China Indicts U.S., British Investigators

July 14, 2014 10:28 am | by Gillian Wong, Associated Press | News | Comments

Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.